The	O
interleukin	B-protein
2	I-protein
CD28-responsive	I-protein
complex	I-protein
contains	O
at	O
least	O
three	O
members	O
of	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
family	I-protein
:	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O

Optimal	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
at	O
least	O
two	O
signals	O
.	O

One	O
signal	O
can	O
be	O
delivered	O
by	O
the	O
antigen-specific	B-protein
T-cell	I-protein
receptor	I-protein
,	O
and	O
the	O
second	O
signal	O
is	O
provided	O
by	O
the	O
costimulatory	O
molecule	O
(	O
s	O
)	O
delivered	O
by	O
the	O
antigen-presenting	B-cell_type
cell	I-cell_type
.	O

CD28	B-protein
is	O
a	O
T-cell	B-protein
surface	I-protein
molecule	I-protein
and	O
stimulation	O
through	O
this	O
protein	O
plays	O
an	O
important	O
role	O
in	O
delivering	O
the	O
second	O
activation	O
signal	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
CD28	B-protein
-mediated	O
signal	O
transduction	O
involves	O
the	O
rel	B-protein
family	I-protein
proteins	I-protein
--	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O

Treatment	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
results	O
in	O
augmentation	O
of	O
nuclear	B-protein
c-Rel	I-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
,	O
and	O
this	O
augmentation	O
can	O
occur	O
in	O
the	O
presence	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

It	O
is	O
also	O
shown	O
in	O
this	O
report	O
that	O
,	O
in	O
response	O
to	O
PMA/anti-CD28	B-protein
mAb	I-protein
or	O
anti-CD3/anti-CD28	B-protein
mAb	I-protein
,	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
are	O
associated	O
with	O
CD28-responsive	B-DNA
element	I-DNA
present	O
in	O
the	O
promoter	B-DNA
of	O
the	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
gene	I-DNA
.	O

The	O
functional	O
significance	O
of	O
c-Rel	B-protein
involvement	O
in	O
the	O
CD28-responsive	B-protein
complex	I-protein
is	O
demonstrated	O
by	O
transient	O
transfection	O
analysis	O
,	O
where	O
cotransfection	O
of	O
c-Rel	B-protein
augments	O
the	O
level	O
of	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
the	O
CD28-responsive	B-DNA
element	I-DNA
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

90	NULL
,	NULL
pp	NULL
.	NULL

1696-1700	NULL
,	NULL
March	NULL
1993	NULL
Immunology	NULL
The	NULL
interleukin	NULL
2	NULL
CD28-responsive	NULL
complex	NULL
contains	NULL
at	NULL
least	NULL
three	NULL
members	NULL
of	NULL
the	NULL
NF	NULL
B	NULL
family	NULL
:	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
PaAritosH	NULL
Gnxosx*	NULL
,	NULL
TsE-Hua	NULL
Tant	NULL
?	NULL

,	NULL
Nancy	NULL
R.	NULL
Rice	NULL
$	NULL
§	NULL
,	NULL
Antonito	NULL
Sica*	NULL
,	NULL
anp	NULL
HowaArp	NULL
A	NULL
.	NULL

Young*	NULL
*Laboratory	NULL
of	NULL
Experimental	NULL
Immunology	NULL
,	NULL
Biological	NULL
Response	NULL
Modifiers	NULL
Program	NULL
,	NULL
$	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Virology	NULL
and	NULL
Carcinogenesis	NULL
,	NULL
ABL-Basic	NULL
Research	NULL
Program	NULL
,	NULL
and	NULL
*Biological	NULL
Carcinogenesis	NULL
Development	NULL
Program	NULL
,	NULL
Program	NULL
Resources/DynCorp	NULL
.	NULL

,	NULL
Inc.	NULL
,	NULL
National	NULL
Cancer	NULL
Institute-Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
21702-1201	NULL
Communicated	NULL
by	NULL
Ray	NULL
D.	NULL
Owen	NULL
,	NULL
December	NULL
2	NULL
,	NULL
1992	NULL
(	NULL
received	NULL
for	NULL
review	NULL
September	NULL
28	NULL
,	NULL
1992	NULL
)	NULL
ABSTRACT	NULL
Optimal	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
requires	NULL
at	NULL
least	NULL
two	NULL
signals	NULL
.	NULL

One	NULL
signal	NULL
can	NULL
be	NULL
delivered	NULL
by	NULL
the	NULL
antigen-specific	NULL
T-cell	NULL
receptor	NULL
,	NULL
and	NULL
the	NULL
second	NULL
signal	NULL
is	NULL
provided	NULL
by	NULL
the	NULL
costimulatory	NULL
molecule	NULL
(	NULL
s	NULL
)	NULL
delivered	NULL
by	NULL
the	NULL
antigen-presenting	NULL
cell	NULL
.	NULL

CD28	NULL
is	NULL
a	NULL
T-cell	NULL
surface	NULL
molecule	NULL
and	NULL
stimulation	NULL
through	NULL
this	NULL
protein	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
delivering	NULL
the	NULL
second	NULL
activation	NULL
signal	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
show	NULL
that	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
,	NULL
CD28-mediated	NULL
signal	NULL
transduction	NULL
involves	NULL
the	NULL
rel	NULL
family	NULL
proteins-c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p6S	NULL
.	NULL

Treatment	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
anti-CD28	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
results	NULL
in	NULL
augmentation	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
,	NULL
and	NULL
this	NULL
augmentation	NULL
can	NULL
occur	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
immunosuppres-sant	NULL
cyclosporin	NULL
A	NULL
.	NULL

It	NULL
is	NULL
also	NULL
shown	NULL
in	NULL
this	NULL
report	NULL
that	NULL
,	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
mAb	NULL
or	NULL
anti-CD3/anti-CD28	NULL
mAb	NULL
,	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
are	NULL
associated	NULL
with	NULL
CD28	NULL
-responsive	NULL
element	NULL
present	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
interleukin	NULL
2	NULL
gene	NULL
.	NULL

The	NULL
functional	NULL
significance	NULL
of	NULL
c-Rel	NULL
involvement	NULL
in	NULL
the	NULL
CD28	NULL
-responsive	NULL
complex	NULL
is	NULL
demonstrated	NULL
by	NULL
transient	NULL
transfection	NULL
analysis	NULL
,	NULL
where	NULL
cotransfection	NULL
of	NULL
c-Rel	NULL
augments	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
a	NULL
chloramphenicol	NULL
acetyltransferase	NULL
reporter	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
CD28-responsive	NULL
element	NULL
.	NULL

A	NULL
key	NULL
activation	NULL
pathway	NULL
in	NULL
the	NULL
T-cell-mediated	NULL
immune	NULL
response	NULL
involves	NULL
the	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
-CD3	NULL
complex	NULL
.	NULL

Although	NULL
the	NULL
specificity	NULL
of	NULL
T-cell	NULL
activation	NULL
is	NULL
determined	NULL
by	NULL
the	NULL
TCR	NULL
,	NULL
TCR	NULL
signaling	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
T-cell	NULL
proliferation	NULL
and	NULL
production	NULL
of	NULL
lymphokines	NULL
[	NULL
e.g	NULL
.	NULL

,	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
interferon	NULL
y	NULL
,	NULL
etc	NULL
.	NULL
]	NULL

(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Accessory	NULL
cell-derived	NULL
costimulatory	NULL
signals	NULL
are	NULL
also	NULL
required	NULL
for	NULL
optimal	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
these	NULL
costimulatory	NULL
signals	NULL
,	NULL
induction	NULL
of	NULL
a	NULL
state	NULL
of	NULL
clonal	NULL
anergy	NULL
has	NULL
been	NULL
proposed	NULL
(	NULL
3	NULL
,	NULL
5-7	NULL
)	NULL
.	NULL

A	NULL
T-cell	NULL
surface	NULL
molecule	NULL
,	NULL
CD28	NULL
,	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
costimulation	NULL
process	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
,	NULL
and	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
recently	NULL
that	NULL
induction	NULL
of	NULL
anergy	NULL
in	NULL
T-cell	NULL
clones	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
the	NULL
CD28-mediated	NULL
costimulatory	NULL
signal	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
subsequent	NULL
production	NULL
of	NULL
IL-2	NULL
via	NULL
CD28	NULL
cell	NULL
surface	NULL
molecule	NULL
triggering	NULL
is	NULL
distinct	NULL
and	NULL
different	NULL
from	NULL
the	NULL
TCR-medifated	NULL
pathway	NULL
(	NULL
9	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

A	NULL
natural	NULL
ligand	NULL
of	NULL
CD28	NULL
,	NULL
B7/BB1	NULL
,	NULL
has	NULL
recently	NULL
been	NULL
identified	NULL
(	NULL
13	NULL
)	NULL
,	NULL
and	NULL
cellular	NULL
interaction	NULL
mediated	NULL
by	NULL
CD28	NULL
and	NULL
the	NULL
B-cell	NULL
activation	NULL
antigen	NULL
B7/BB1	NULL
may	NULL
represent	NULL
an	NULL
important	NULL
functional	NULL
interaction	NULL
between	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
CD28-mediated	NULL
signal	NULL
transduction	NULL
pathway	NULL
have	NULL
yet	NULL
to	NULL
be	NULL
fully	NULL
characterized	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
CD28-responsive	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
in	NULL
the	NULL
IL-2	NULL
gene	NULL
promoter	NULL
has	NULL
been	NULL
identified	NULL
and	NULL
shown	NULL
to	NULL
have	NULL
enhancer	NULL
activity	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
CD28RE	NULL
has	NULL
been	NULL
found	NULL
in	NULL
5	NULL
'	NULL
upstream	NULL
regions	NULL
of	NULL
many	NULL
lymphokine	NULL
genes	NULL
(	NULL
17	NULL
)	NULL
.	NULL

CD28-mediated	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
by	NULL
Vandenberghe	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

1696	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
involved	NULL
in	NULL
the	NULL
CD28-mediated	NULL
signal	NULL
transduction	NULL
pathway	NULL
has	NULL
not	NULL
been	NULL
fully	NULL
characterized	NULL
.	NULL

In	NULL
this	NULL
manuscript	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
treatment	NULL
of	NULL
freshly	NULL
purified	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
anti-CD28	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
results	NULL
in	NULL
increased	NULL
nuclear	NULL
c-Rel	NULL
as	NULL
well	NULL
as	NULL
the	NULL
NF	NULL
«	NULL
B	NULL
p50	NULL
and	NULL
p65	NULL
subunits	NULL
,	NULL
and	NULL
this	NULL
increase	NULL
in	NULL
nuclear	NULL
protein	NULL
levels	NULL
is	NULL
resistant	NULL
to	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
in	NULL
response	NULL
to	NULL
PMA/	NULL
anti-CD28	NULL
mAb	NULL
or	NULL
anti-CD3/anti-CD28	NULL
mAb	NULL
,	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
are	NULL
all	NULL
associated	NULL
with	NULL
the	NULL
CD28RE	NULL
.	NULL

Finally	NULL
,	NULL
in	NULL
transient	NULL
transfection	NULL
analysis	NULL
we	NULL
demonstrate	NULL
that	NULL
cotransfection	NULL
of	NULL
a	NULL
c-Rel	NULL
expression	NULL
plasmid	NULL
can	NULL
upregulate	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
expression	NULL
6-fold	NULL
in	NULL
a	NULL
CAT	NULL
vector	NULL
containing	NULL
the	NULL
CD28RE	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Preparation	NULL
of	NULL
T-Cell	NULL
Nuclear	NULL
Extracts	NULL
and	NULL
Western	NULL
Blot	NULL
Analysis	NULL
.	NULL

Freshly	NULL
purified	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
>	NULL
95	NULL
%	NULL
CD3+*	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
2	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
PMA/anti-CD28	NULL
mAb	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
,	NULL
PMA/anti-CD28	NULL
mAb/	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
,	NULL
PMA/ionomycin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
or	NULL
PMA/	NULL
ionomycin/CsA	NULL
for	NULL
7	NULL
hr	NULL
(	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
CsA	NULL
for	NULL
30	NULL
min	NULL
before	NULL
other	NULL
stimuli	NULL
were	NULL
added	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
procedure	NULL
of	NULL
D.	NULL
G.	NULL
Kelvin	NULL
,	NULL
G.	NULL
White	NULL
,	NULL
D.	NULL
L.	NULL
Longo	NULL
,	NULL
and	NULL
D.	NULL
F.	NULL
Ferris	NULL
(	NULL
personal	NULL
commu-nication	NULL
)	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
analyzed	NULL
by	NULL
SDS/PAGE	NULL
(	NULL
10	NULL
%	NULL
acrylamide	NULL
)	NULL
followed	NULL
by	NULL
immunoblotting	NULL
with	NULL
rabbit	NULL
anti-c-Rel/anti-p50/anti-p65	NULL
antibodies	NULL
.	NULL

Immunoreactive	NULL
bands	NULL
were	NULL
visualized	NULL
by	NULL
using	NULL
horseradish	NULL
peroxidase-coupled	NULL
goat	NULL
anti-rabbit	NULL
immunoglobulin	NULL
and	NULL
the	NULL
enhanced	NULL
chemilu-minescence	NULL
detection	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Antisera	NULL
.	NULL

The	NULL
antisera	NULL
used	NULL
in	NULL
Western	NULL
blot	NULL
and	NULL
immunoprecipitation	NULL
experiments	NULL
are	NULL
described	NULL
elsewhere	NULL
(	NULL
19	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
anti-human	NULL
c-Rel	NULL
antiserum	NULL
265	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
C-terminal	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
573-587	NULL
)	NULL
,	NULL
anti-human-p50	NULL
antiserum	NULL
1141	NULL
was	NULL
raised	NULL
against	NULL
an	NULL
N-terminal	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
2-15	NULL
)	NULL
,	NULL
and	NULL
anti-p65	NULL
antiserum	NULL
1226	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
C-terminal	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
537-550	NULL
)	NULL
.	NULL

Each	NULL
antiserum	NULL
is	NULL
specific	NULL
for	NULL
its	NULL
protein	NULL
and	NULL
does	NULL
not	NULL
cross-react	NULL
with	NULL
other	NULL
rel	NULL
family	NULL
members	NULL
(	NULL
19	NULL
)	NULL
.	NULL

DNA-Binding	NULL
Assay	NULL
.	NULL

A	NULL
bacterial	NULL
expression	NULL
vector	NULL
for	NULL
human	NULL
c-Rel	NULL
,	NULL
pKKrel	NULL
,	NULL
was	NULL
used	NULL
to	NULL
express	NULL
c-Rel	NULL
protein	NULL
in	NULL
Escherichia	NULL
coli	NULL
(	NULL
20	NULL
)	NULL
,	NULL
and	NULL
the	NULL
bacterial	NULL
lysate	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Control	NULL
bacterial	NULL
lysate	NULL
was	NULL
prepared	NULL
from	NULL
E.	NULL
coli	NULL
containing	NULL
only	NULL
the	NULL
expression	NULL
vector	NULL
.	NULL

Electrophoretic	NULL
Abbreviations	NULL
:	NULL
TCR	NULL
,	NULL
T-cell	NULL
receptor	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
CD28RE	NULL
,	NULL
CD28-responsive	NULL
element	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
;	NULL
CD28RC	NULL
,	NULL
CD28RE-binding	NULL
protein	NULL
complex	NULL
.	NULL

*Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
Baylor	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
77030	NULL
.	NULL

Immunology	NULL
:	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

mobility-shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
with	NULL
bacterial	NULL
extracts	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

The	NULL
buffer	NULL
used	NULL
in	NULL
EMSA	NULL
with	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
has	NULL
also	NULL
been	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Oligonucleotides	NULL
used	NULL
in	NULL
EMSA	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
1	NULL
,	NULL
CD28RE	NULL
(	NULL
-164	NULL
to	NULL
-149	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
)	NULL
,	NULL
AAAGAAATTC-CAAAGA	NULL
;	NULL
2	NULL
,	NULL
CD28RE	NULL
mutant	NULL
,	NULL
AAAGAAGCCTCAAAGA	NULL
;	NULL
3	NULL
,	NULL
IL-2	NULL
receptor	NULL
a	NULL
«	NULL
B	NULL
(	NULL
-271	NULL
to	NULL
-257	NULL
of	NULL
the	NULL
NF	NULL
«	NULL
B-binding	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
a	NULL
promoter	NULL
)	NULL
,	NULL
GATCAGGGGAATC-TCCC	NULL
;	NULL
4	NULL
,	NULL
Spl	NULL
(	NULL
-80	NULL
to	NULL
-44	NULL
of	NULL
Spl-binding	NULL
sites	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
)	NULL
,	NULL
GATCGGGAGGCGTGGCCTGGGCGGGACTGGG-GAGTGGCGA	NULL
.	NULL

UV	NULL
Crosslinking	NULL
and	NULL
Immunoprecipitation	NULL
.	NULL

The	NULL
bromouridine-substituted	NULL
CD28RE	NULL
oligonucleotide	NULL
was	NULL
synthesized	NULL
on	NULL
a	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Applied	NULL
Biosystem	NULL
,	NULL
model	NULL
392	NULL
)	NULL
.	NULL

UV	NULL
crosslinking	NULL
and	NULL
immunoprecipitation	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
procedure	NULL
described	NULL
by	NULL
Kochel	NULL
and	NULL
Rice	NULL
(	NULL
24	NULL
)	NULL
with	NULL
the	NULL
following	NULL
modification	NULL
:	NULL
UV	NULL
irradiation	NULL
was	NULL
performed	NULL
on	NULL
the	NULL
gel	NULL
after	NULL
EMSA	NULL
.	NULL

The	NULL
complex	NULL
was	NULL
excised	NULL
and	NULL
protein	NULL
was	NULL
eluted	NULL
according	NULL
to	NULL
the	NULL
described	NULL
procedure	NULL
(	NULL
25	NULL
)	NULL
.	NULL

After	NULL
precipitating	NULL
the	NULL
proteins	NULL
with	NULL
acetone	NULL
,	NULL
the	NULL
crosslinked	NULL
products	NULL
were	NULL
analyzed	NULL
by	NULL
SDS/PAGE	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
crosslinked	NULL
products	NULL
by	NULL
immunoprecipitation	NULL
,	NULL
the	NULL
eluted	NULL
products	NULL
from	NULL
EMSA	NULL
gel	NULL
were	NULL
used	NULL
as	NULL
a	NULL
starting	NULL
material	NULL
for	NULL
immunoprecipitation	NULL
as	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

RESULTS	NULL
It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
the	NULL
CD28	NULL
costimulatory	NULL
signal	NULL
can	NULL
act	NULL
through	NULL
the	NULL
«	NULL
B	NULL
element	NULL
(	NULL
26	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
CD28RE	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
has	NULL
been	NULL
mapped	NULL
to	NULL
a	NULL
distinct	NULL
sequence	NULL
that	NULL
is	NULL
different	NULL
from	NULL
the	NULL
previously	NULL
identified	NULL
xB	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
17	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
NF	NULL
«	NULL
B	NULL
family	NULL
proteins	NULL
(	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
c-Rel	NULL
)	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
CD28	NULL
signaling	NULL
pathway	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
purified	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
alone	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
alone	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
anti-c-Rel	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
,	NULL
anti-p50	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

16	NULL
)	NULL
,	NULL
or	NULL
anti-p65	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

1c	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
medium	NULL
alone	NULL
or	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
level	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
,	NULL
while	NULL
PMA	NULL
did	NULL
upregulate	NULL
the	NULL
levels	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
maximum	NULL
induction	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
was	NULL
observed	NULL
after	NULL
the	NULL
combined	NULL
PMA/anti-CD28	NULL
mAb	NULL
treatment	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
for	NULL
NF	NULL
«	NULL
B	NULL
p50	NULL
and	NULL
p65	NULL
,	NULL
as	NULL
maximum	NULL
inductions	NULL
were	NULL
observed	NULL
after	NULL
combined	NULL
PMA	NULL
/anti-CD28	NULL
mAb	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
b	NULL
and	NULL
c	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
augmentation	NULL
of	NULL
the	NULL
PMA	NULL
response	NULL
is	NULL
specific	NULL
to	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
the	NULL
experiment	NULL
was	NULL
repeated	NULL
with	NULL
PMA	NULL
with	NULL
or	NULL
without	NULL
anti-CD2	NULL
mAb	NULL
.	NULL

Unlike	NULL
the	NULL
result	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
anti-CD2	NULL
mAb	NULL
did	NULL
not	NULL
augment	NULL
the	NULL
PMA	NULL
response	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
effect	NULL
is	NULL
specific	NULL
to	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
is	NULL
not	NULL
reproduced	NULL
with	NULL
another	NULL
T-cell	NULL
reactive	NULL
antibody	NULL
.	NULL

Induction	NULL
of	NULL
T-cell	NULL
proliferation	NULL
and	NULL
IL-2	NULL
expression	NULL
by	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
mAb	NULL
is	NULL
resistant	NULL
to	NULL
CsA	NULL
(	NULL
27	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
major	NULL
transcriptional	NULL
stimulation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
mediated	NULL
through	NULL
the	NULL
TCR	NULL
complex	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
(	NULL
28	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
upregulation	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
was	NULL
mediated	NULL
through	NULL
the	NULL
CD28-signaling	NULL
pathway	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA/anti-CD28	NULL
mAb	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
CsA	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
examined	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
df	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
nuclear	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
in	NULL
response	NULL
to	NULL
PMA/anti-CD28	NULL
mAb	NULL
was	NULL
resistant	NULL
to	NULL
CsA	NULL
,	NULL
consistent	NULL
with	NULL
involvement	NULL
of	NULL
the	NULL
CD28-signaling	NULL
pathway	NULL
.	NULL

In	NULL
a	NULL
control	NULL
experiment	NULL
,	NULL
the	NULL
upregulation	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
by	NULL
PMA/calcium	NULL
ionophore	NULL
(	NULL
ionomycin	NULL
)	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
was	NULL
found	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
CsA	NULL
as	NULL
expected	NULL
(	NULL
Fig	NULL
.	NULL

1g	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
CsA	NULL
treatment	NULL
did	NULL
not	NULL
block	NULL
the	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
1697	NULL
<	NULL
I	NULL
w	NULL
9	NULL
co	NULL
el	NULL
co	NULL
O	NULL
O	NULL
O	NULL
o	NULL
o	NULL
o	NULL
O	NULL
o	NULL
o	NULL
%	NULL
>	NULL
£	NULL
#	NULL
&	NULL
<	NULL
o	NULL
<	NULL
I	NULL
<	NULL
4	NULL
<	NULL
2	NULL
Q	NULL
2	NULL
2	NULL
2	NULL
I	NULL
a.	NULL
s	NULL
a.	NULL
I	NULL
a	NULL
_	NULL
o	NULL
.	NULL

(	NULL
a	NULL
)	NULL
e	NULL
ae	NULL
.	NULL

--	NULL
c-Rel	NULL
-	NULL
»	NULL
wam	NULL
aao	NULL
(	NULL
c	NULL
)	NULL
(	NULL
b	NULL
)	NULL
«	NULL
=	NULL
»	NULL
amp	NULL
«	NULL
«	NULL
»	NULL
GBD	NULL
--	NULL
pS	NULL
)	NULL
-	NULL
»	NULL
«	NULL
--	NULL
-	NULL
(	NULL
c	NULL
)	NULL
(	NULL
c	NULL
)	NULL
m=	NULL
mt	NULL
]	NULL
--	NULL
pos	NULL
-	NULL
wae	NULL
amit	NULL
(	NULL
{	NULL
)	NULL
1	NULL
2	NULL
.	NULL

%	NULL
--	NULL
4	NULL
1°	NULL
2	NULL
$	NULL
5	NULL
-	NULL
Z	NULL
5	NULL
5	NULL
£	NULL
£	NULL
o	NULL
o	NULL
<	NULL
%	NULL
&	NULL
c	NULL
o	NULL
2°	NULL
4	NULL
<	NULL
4	NULL
2	NULL
3	NULL
1	NULL
.	NULL

&	NULL
(	NULL
g	NULL
)	NULL
tm	NULL
«	NULL
«	NULL
»	NULL
--	NULL
c-Rel	NULL
10	NULL
203	NULL
FiG	NULL
.	NULL

1.	NULL
.	NULL

Upregulation	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
6	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
from	NULL
purified	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
anti-c-Rel	NULL
antiserum	NULL
265	NULL
(	NULL
a	NULL
)	NULL
,	NULL
anti-p50	NULL
antiserum	NULL
1141	NULL
(	NULL
b	NULL
)	NULL
,	NULL
and	NULL
anti-p65	NULL
antiserum	NULL
1226	NULL
(	NULL
c	NULL
)	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
,	NULL
extract	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
;	NULL
2	NULL
,	NULL
extract	NULL
from	NULL
PMA-treated	NULL
cells	NULL
;	NULL
3	NULL
,	NULL
extract	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
alone	NULL
;	NULL
4	NULL
,	NULL
extract	NULL
from	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
mAb-treated	NULL
cells	NULL
.	NULL

(	NULL
d-f	NULL
)	NULL
Effects	NULL
of	NULL
CsA	NULL
on	NULL
treatments	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
PMA/anti-CD28	NULL
mAb	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
of	NULL
CsA	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
the	NULL
same	NULL
anti-c-Rel	NULL
(	NULL
d	NULL
)	NULL
,	NULL
anti-p50	NULL
(	NULL
e	NULL
)	NULL
,	NULL
and	NULL
anti-p65	NULL
(	NULL
f	NULL
)	NULL
antisera	NULL
.	NULL

(	NULL
g	NULL
)	NULL
Sensitivity	NULL
of	NULL
upregulation	NULL
of	NULL
nuclear	NULL
c-Rel	NULL
by	NULL
PMA/ionomycin	NULL
to	NULL
CsA	NULL
is	NULL
shown	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
extract	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
extract	NULL
after	NULL
PMA/ionomycin-treated	NULL
cells	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
extract	NULL
after	NULL
PMA/ionomycin/CsA	NULL
treatment	NULL
.	NULL

upregulation	NULL
of	NULL
nuclear	NULL
rel	NULL
family	NULL
proteins	NULL
completely	NULL
,	NULL
no	NULL
IL-2	NULL
production	NULL
was	NULL
observed	NULL
after	NULL
this	NULL
treatment	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
is	NULL
that	NULL
the	NULL
level	NULL
of	NULL
rel	NULL
family	NULL
proteins	NULL
that	NULL
remained	NULL
after	NULL
PMA/ionomycin/CsA	NULL
treatment	NULL
was	NULL
not	NULL
sufficient	NULL
for	NULL
gene	NULL
transcription	NULL
(	NULL
see	NULL
Discussion	NULL
)	NULL
.	NULL

As	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
CD28RE	NULL
forms	NULL
specific	NULL
protein-DNA	NULL
complexes	NULL
after	NULL
stimulation	NULL
through	NULL
the	NULL
CD28	NULL
pathway	NULL
(	NULL
17	NULL
)	NULL
,	NULL
we	NULL
next	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
members	NULL
of	NULL
the	NULL
NF	NULL
«	NULL
B	NULL
family	NULL
that	NULL
were	NULL
upregulated	NULL
by	NULL
PMA/anti-CD28	NULL
mAb	NULL
treatment	NULL
could	NULL
interact	NULL
with	NULL
the	NULL
CD28RE	NULL
.	NULL

An	NULL
EMSA	NULL
of	NULL
the	NULL
CD28RE	NULL
using	NULL
a	NULL
bacterial	NULL
extract	NULL
containing	NULL
c-Rel	NULL
revealed	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
DNA-protein	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
DNA-protein	NULL
complex	NULL
was	NULL
blocked	NULL
by	NULL
competition	NULL
with	NULL
unlabeled	NULL
CD28RE	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
and	NULL
an	NULL
IL-2	NULL
receptor	NULL
a	NULL
«	NULL
B	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
the	NULL
nonspecific	NULL
oligonucleotides	NULL
Spl	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
tax	NULL
responsive	NULL
element	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
or	NULL
an	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
silencer	NULL
region	NULL
of	NULL
the	NULL
interferon	NULL
y	NULL
gene	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
CD28RE	NULL
is	NULL
also	NULL
recognized	NULL
by	NULL
NF	NULL
«	NULL
B	NULL
p50	NULL
,	NULL
an	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
affinity-purified	NULL
,	NULL
bacterially	NULL
expressed	NULL
p50	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
R.	NULL
Roeder	NULL
,	NULL
The	NULL
Rockefeller	NULL
University	NULL
)	NULL
.	NULL

In	NULL
this	NULL
assay	NULL
,	NULL
labeled	NULL
IL-2	NULL
receptor	NULL
a	NULL
«	NULL
B	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
while	NULL
unlabeled	NULL
CD28RE	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

While	NULL
the	NULL
DNA-protein	NULL
complex	NULL
was	NULL
blocked	NULL
by	NULL
competition	NULL
with	NULL
unlabeled	NULL
«	NULL
B	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
no	NULL
competition	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
unlabeled	NULL
CD28RE	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
that	NULL
bacterially	NULL
expressed	NULL
NF	NULL
«	NULL
B	NULL
p50	NULL
does	NULL
not	NULL
recognize	NULL
the	NULL
CD28RE	NULL
sequence	NULL
.	NULL

When	NULL
an	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
NF	NULL
«	NULL
B	NULL
p50	NULL
and	NULL
a	NULL
labeled	NULL
CD28RE	NULL
oligonucleotide	NULL
,	NULL
no	NULL
DNA	NULL
1698	NULL
Immunology	NULL
:	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

A	NULL
CD28BRE	NULL
NFxB	NULL
_	NULL
SP1	NULL
§	NULL
_	NULL
TC	NULL
--	NULL
-	NULL
]	NULL
&	NULL
@	NULL
o	NULL
o	NULL
=	NULL
]	NULL
0	NULL
CC	NULL
&	NULL
O	NULL
O	NULL
O	NULL
0	NULL
0	NULL
0	NULL
u	NULL
r-	NULL
w	NULL
>	NULL
--	NULL
Free-	NULL
»	NULL
Probe	NULL
B	NULL
p50	NULL
[	NULL
OI	NULL
L	NULL
m	NULL
-	NULL
%	NULL
x	NULL
o	NULL
«	NULL
-	NULL
,	NULL
u-	NULL
o	NULL
a	NULL
.	NULL

Competitor	NULL
:	NULL
I	NULL
2	NULL
{	NULL
w	NULL
FiG	NULL
.	NULL

2	NULL
.	NULL

Recognition	NULL
of	NULL
CD28RE	NULL
by	NULL
bacterially	NULL
expressed	NULL
c-Rel	NULL
,	NULL
but	NULL
not	NULL
p50	NULL
.	NULL

(	NULL
4	NULL
)	NULL
EMSA	NULL
using	NULL
3	NULL
ug	NULL
of	NULL
total	NULL
protein	NULL
from	NULL
control	NULL
bacterial	NULL
lysate	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
lysate	NULL
from	NULL
cells	NULL
expressing	NULL
c-Rel	NULL
protein	NULL
(	NULL
lanes	NULL
3-8	NULL
)	NULL
.	NULL

A	NULL
double-stranded	NULL
*°P-labeled	NULL
oligonucleotide	NULL
(	NULL
1	NULL
ng	NULL
)	NULL
consisting	NULL
of	NULL
the	NULL
CD28RE	NULL
site	NULL
(	NULL
AAAGAAATTCCAAAGA	NULL
;	NULL
-164	NULL
to	NULL
-149	NULL
)	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
17	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

Competition	NULL
of	NULL
the	NULL
DNA-protein	NULL
complex	NULL
was	NULL
with	NULL
unlabeled	NULL
CD28RE	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
IL-2	NULL
receptor	NULL
a	NULL
«	NULL
B	NULL
site	NULL
(	NULL
GATCAGGGGAATCTCCC	NULL
;	NULL
ref	NULL
.	NULL

29	NULL
)	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
,	NULL
and	NULL
Spl	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
free	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
using	NULL
affinity-purified	NULL
,	NULL
bacterially	NULL
expressed	NULL
p50	NULL
.	NULL

Probe	NULL
was	NULL
a	NULL
P-labeled	NULL
IL-2	NULL
receptor	NULL
a	NULL
«	NULL
B	NULL
site	NULL
.	NULL

Unlabeled	NULL
CD28RE	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
IL-2	NULL
receptor	NULL
a	NULL
«	NULL
B	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
and	NULL
Spl	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
oligonucleotides	NULL
were	NULL
used	NULL
as	NULL
competitors	NULL
(	NULL
200-fold	NULL
molar	NULL
excess	NULL
)	NULL
.	NULL

protein	NULL
complex	NULL
was	NULL
obtained	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
CD28RE	NULL
can	NULL
be	NULL
recognized	NULL
by	NULL
bacterial-derived	NULL
c-Rel	NULL
but	NULL
not	NULL
p50	NULL
.	NULL

We	NULL
next	NULL
characterized	NULL
the	NULL
inducible	NULL
CD28RE-binding	NULL
protein	NULL
complex	NULL
(	NULL
CD28RC	NULL
)	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
PMA/	NULL
anti-CD28	NULL
mAb-treated	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

In	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
CD28RE	NULL
oligonucleotide	NULL
,	NULL
this	NULL
complex	NULL
(	NULL
CD28RC	NULL
)	NULL
was	NULL
blocked	NULL
by	NULL
competition	NULL
with	NULL
unlabeled	NULL
CD28RE	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
but	NULL
not	NULL
by	NULL
the	NULL
mutant	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
was	NULL
not	NULL
induced	NULL
after	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
alone	NULL
,	NULL
but	NULL
it	NULL
was	NULL
induced	NULL
(	NULL
although	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
)	NULL
by	NULL
treatment	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
induction	NULL
was	NULL
observed	NULL
in	NULL
T-cell	NULL
extracts	NULL
from	NULL
10	NULL
separate	NULL
donors	NULL
.	NULL

When	NULL
a	NULL
gel-shift	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
CD28RE	NULL
using	NULL
a	NULL
PMA	NULL
T-cell	NULL
nuclear	NULL
extract	NULL
,	NULL
an	NULL
inducible	NULL
DNA-protein	NULL
complex	NULL
was	NULL
obtained	NULL
that	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
following	NULL
PMA	NULL
treatment	NULL
alone	NULL
but	NULL
in	NULL
a	NULL
much	NULL
reduced	NULL
level	NULL
compared	NULL
to	NULL
PMA/anti-CD28	NULL
mAb	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
inducible	NULL
protein-DNA	NULL
complex	NULL
,	NULL
UV	NULL
crosslinking	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
bromouridine-substituted	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
A	NULL
Lu	NULL
LJ	NULL
Co	NULL
k	NULL
J	NULL
&	NULL
&	NULL
3	NULL
.	NULL

o	NULL
-a	NULL
£	NULL
Competitor	NULL
:	NULL
I	NULL
I	NULL
o	NULL
-	NULL
o	NULL
~	NULL
1	NULL
2	NULL
3	NULL
4	NULL
co	NULL
co	NULL
8	NULL
-	NULL
a	NULL
B	NULL
x	NULL
C	NULL
O	NULL
(	NULL
3	NULL
AAAGAAATTCCAAAGA	NULL
3	NULL
“	NULL
:	NULL
g	NULL
pS	NULL
o	NULL
o_	NULL
8	NULL
97-	NULL
_	NULL
69	NULL
46	NULL
1	NULL
2	NULL
3	NULL
D	NULL
E	NULL
e	NULL
2	NULL
_	NULL
2	NULL
E	NULL
o	NULL
w	NULL
2	NULL
&	NULL
O	NULL
u	NULL
)	NULL
1	NULL
w	NULL
©	NULL
1	NULL
u	NULL
)	NULL
«	NULL
©	NULL
1	NULL
G	NULL
iff	NULL
£	NULL
$	NULL
f	NULL
2	NULL
g	NULL
&	NULL
f	NULL
§	NULL
&	NULL
T	NULL
&	NULL
5	NULL
§	NULL
&	NULL
E	NULL
97—	NULL
«	NULL
mmane	NULL
69	NULL
-	NULL
97	NULL
-	NULL
o	NULL
ais	NULL
69	NULL
46	NULL
-	NULL
we	NULL
46	NULL
-	NULL
.	NULL

1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
1	NULL
20	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Characterization	NULL
of	NULL
CD28RC	NULL
.	NULL

(	NULL
4	NULL
)	NULL
EMSA	NULL
of	NULL
T-cell	NULL
nuclear	NULL
extract	NULL
after	NULL
treatment	NULL
of	NULL
cells	NULL
either	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
with	NULL
PMA/anti-CD28	NULL
mAb	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
.	NULL

Assay	NULL
was	NULL
performed	NULL
with	NULL
*P-labeled	NULL
CD28RE	NULL
oligonucleotide	NULL
.	NULL

Competitors	NULL
(	NULL
100-fold	NULL
molar	NULL
excess	NULL
)	NULL
were	NULL
unlabeled	NULL
CD28RE	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
a	NULL
mutant	NULL
of	NULL
CD28RE	NULL
(	NULL
AAAGAAGCCTCAAAGA	NULL
)	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Sequence	NULL
of	NULL
bromouridine-substituted	NULL
CD28RE	NULL
probe	NULL
,	NULL
where	NULL
X	NULL
indicates	NULL
position	NULL
of	NULL
bromouridine	NULL
substitution	NULL
.	NULL

(	NULL
C	NULL
)	NULL
UV	NULL
crosslinking	NULL
analysis	NULL
of	NULL
CD28RC	NULL
.	NULL

Probe	NULL
used	NULL
was	NULL
the	NULL
P-labeled	NULL
oligonucleotide	NULL
shown	NULL
in	NULL
B	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
,	NULL
molecular	NULL
size	NULL
markers	NULL
(	NULL
kDa	NULL
)	NULL
;	NULL
2	NULL
,	NULL
nuclear	NULL
extract	NULL
from	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
mAb	NULL
;	NULL
3	NULL
,	NULL
nuclear	NULL
extract	NULL
from	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
mAb	NULL
.	NULL

(	NULL
D	NULL
and	NULL
E	NULL
)	NULL
Immunoprecipitation	NULL
of	NULL
UV-crosslinked	NULL
CD28RC	NULL
using	NULL
extract	NULL
from	NULL
PMA/anti-CD28	NULL
mAb-treated	NULL
cells	NULL
(	NULL
D	NULL
)	NULL
and	NULL
from	NULL
anti-CD3/anti-CD28	NULL
mAb-treated	NULL
cells	NULL
(	NULL
F	NULL
)	NULL
.	NULL

For	NULL
immunoprecipitation	NULL
experiments	NULL
,	NULL
the	NULL
UV-crosslinked	NULL
product	NULL
eluted	NULL
from	NULL
EMSA	NULL
gel	NULL
was	NULL
boiled	NULL
in	NULL
1	NULL
%	NULL
SDS	NULL
,	NULL
diluted	NULL
,	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
the	NULL
respective	NULL
antiserum	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
,	NULL
molecular	NULL
size	NULL
markers	NULL
(	NULL
kDa	NULL
)	NULL
;	NULL
2	NULL
,	NULL
preimmune	NULL
serum	NULL
;	NULL
3	NULL
,	NULL
c-Rel	NULL
antiserum	NULL
265	NULL
;	NULL
4	NULL
,	NULL
p50	NULL
antiserum	NULL
1141	NULL
;	NULL
5	NULL
,	NULL
p65	NULL
antiserum	NULL
1226	NULL
;	NULL
6	NULL
,	NULL
irrelevant	NULL
antiserum	NULL
HY103	NULL
.	NULL

probe	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Three	NULL
major	NULL
protein	NULL
bands	NULL
were	NULL
obtained	NULL
that	NULL
migrated	NULL
with	NULL
molecular	NULL
masses	NULL
slightly	NULL
higher	NULL
than	NULL
85	NULL
,	NULL
65	NULL
,	NULL
and	NULL
50	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
a	NULL
physiologically	NULL
relevant	NULL
stimulus	NULL
also	NULL
can	NULL
induce	NULL
these	NULL
proteins	NULL
,	NULL
anti-CD3	NULL
mAb	NULL
OKT3	NULL
was	NULL
used	NULL
instead	NULL
of	NULL
PMA	NULL
.	NULL

A	NULL
similar	NULL
result	NULL
was	NULL
obtained	NULL
with	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
mAb	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

PMA	NULL
treatment	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
treatment	NULL
alone	NULL
also	NULL
induced	NULL
these	NULL
proteins	NULL
,	NULL
but	NULL
the	NULL
level	NULL
of	NULL
induction	NULL
was	NULL
lower	NULL
than	NULL
with	NULL
PMA/anti-CD28	NULL
mAb	NULL
or	NULL
anti-CD3/anti-CD28	NULL
mAb	NULL
treatment	NULL
,	NULL
respectively	NULL
,	NULL
just	NULL
as	NULL
in	NULL
EMSA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
mAb	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
was	NULL
similar	NULL
to	NULL
PMA/anti-CD28	NULL
mAb	NULL
treatment	NULL
with	NULL
Immunology	NULL
:	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Cotransfection	NULL
of	NULL
c-Rel	NULL
in	NULL
Jurkat	NULL
cells	NULL
augments	NULL
expression	NULL
of	NULL
a	NULL
CAT	NULL
plasmid	NULL
containing	NULL
four	NULL
copies	NULL
of	NULL
CD28RC-binding	NULL
site	NULL
Induction	NULL
,	NULL
Constructs	NULL
-fold	NULL
pBLCAT2	NULL
+	NULL
pRSVcREL	NULL
1	NULL
4xCD28RE-CAT	NULL
+	NULL
pSRSPA	NULL
1	NULL
4xCD28RE-CAT	NULL
+	NULL
pRSVcREL	NULL
6	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
by	NULL
electroporation	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
plus	NULL
10	NULL
ug	NULL
of	NULL
expression	NULL
vector	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
48	NULL
hr	NULL
and	NULL
CAT	NULL
ELISA	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
the	NULL
average	NULL
of	NULL
six	NULL
different	NULL
experiments	NULL
(	NULL
range	NULL
from	NULL
4x	NULL
to	NULL
7.2x	NULL
)	NULL
.	NULL

Reporter	NULL
plasmids	NULL
were	NULL
4xCD28RE-CAT	NULL
,	NULL
containing	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
CD28RE	NULL
(	NULL
one	NULL
copy	NULL
,	NULL
AAAGAAATTCC	NULL
)	NULL
and	NULL
pBLCAT2	NULL
,	NULL
the	NULL
parental	NULL
CAT	NULL
plasmid	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Expression	NULL
plasmids	NULL
were	NULL
pRSVcREL	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
human	NULL
REL	NULL
gene	NULL
and	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
and	NULL
pSRSPA	NULL
,	NULL
the	NULL
parental	NULL
expression	NULL
vector	NULL
(	NULL
20	NULL
)	NULL
.	NULL

respect	NULL
to	NULL
nuclear	NULL
translocation	NULL
of	NULL
rel	NULL
family	NULL
members	NULL
and	NULL
induction	NULL
of	NULL
CD28RC	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL
'	NULL

To	NULL
identify	NULL
the	NULL
proteins	NULL
crosslinked	NULL
to	NULL
the	NULL
CD28RE	NULL
,	NULL
the	NULL
UV-treated	NULL
samples	NULL
were	NULL
boiled	NULL
in	NULL
SDS	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-c-Rel	NULL
,	NULL
anti-p65	NULL
,	NULL
and	NULL
anti-p50	NULL
antisera	NULL
.	NULL

The	NULL
results	NULL
of	NULL
this	NULL
experiment	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3D	NULL
.	NULL

No	NULL
protein	NULL
band	NULL
was	NULL
obtained	NULL
when	NULL
preimmune	NULL
serum	NULL
was	NULL
used	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
c-Rel	NULL
antiserum	NULL
precipitated	NULL
a	NULL
protein	NULL
that	NULL
migrated	NULL
slightly	NULL
slower	NULL
than	NULL
c-Rel	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
its	NULL
being	NULL
bound	NULL
to	NULL
the	NULL
oligonucleotide	NULL
.	NULL

Similarly	NULL
,	NULL
p50	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
p65	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
were	NULL
detected	NULL
by	NULL
the	NULL
anti-p50	NULL
and	NULL
anti-p65	NULL
antisera	NULL
,	NULL
respectively	NULL
.	NULL

No	NULL
protein	NULL
was	NULL
obtained	NULL
when	NULL
an	NULL
irrelevant	NULL
antiserum	NULL
(	NULL
HY103	NULL
)	NULL
was	NULL
used	NULL
for	NULL
immunoprecipitation	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

By	NULL
the	NULL
same	NULL
procedure	NULL
,	NULL
we	NULL
also	NULL
characterized	NULL
the	NULL
DNA-protein	NULL
complex	NULL
obtained	NULL
after	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
mAb	NULL
.	NULL

As	NULL
with	NULL
the	NULL
extract	NULL
from	NULL
PMA/anti-CD28	NULL
mAb-treated	NULL
cells	NULL
,	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
were	NULL
present	NULL
in	NULL
the	NULL
CD28RC	NULL
(	NULL
Fig	NULL
.	NULL

3€	NULL
,	NULL
lanes	NULL
3-5	NULL
)	NULL
.	NULL

The	NULL
in	NULL
vivo	NULL
significance	NULL
of	NULL
the	NULL
association	NULL
between	NULL
CD28RE	NULL
and	NULL
c-Rel	NULL
was	NULL
tested	NULL
by	NULL
cotransfection	NULL
studies	NULL
with	NULL
a	NULL
c-Rel	NULL
expression	NULL
vector	NULL
and	NULL
a	NULL
reporter	NULL
plasmid	NULL
containing	NULL
the	NULL
CAT	NULL
gene	NULL
linked	NULL
to	NULL
four	NULL
copies	NULL
of	NULL
CD28RC-binding	NULL
site	NULL
.	NULL

The	NULL
core-binding	NULL
sequence	NULL
of	NULL
CD28RE	NULL
(	NULL
-164	NULL
to	NULL
-154	NULL
)	NULL
was	NULL
used	NULL
to	NULL
construct	NULL
CD28RE-CAT	NULL
plasmid	NULL
.	NULL

The	NULL
result	NULL
of	NULL
transient	NULL
cotransfection	NULL
into	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
is	NULL
presented	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Cotransfection	NULL
of	NULL
c-Rel	NULL
enhanced	NULL
reporter	NULL
gene	NULL
expression	NULL
by	NULL
~6-fold	NULL
.	NULL

This	NULL
demonstrates	NULL
a	NULL
functional	NULL
interaction	NULL
between	NULL
c-Rel	NULL
and	NULL
CD28RE	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
direct	NULL
interaction	NULL
observed	NULL
in	NULL
UV	NULL
crosslinking	NULL
and	NULL
immunoprecipitation	NULL
experiments	NULL
.	NULL

DISCUSSION	NULL
These	NULL
findings	NULL
strongly	NULL
suggest	NULL
that	NULL
NF	NULL
«	NULL
B	NULL
family	NULL
proteins	NULL
are	NULL
involved	NULL
in	NULL
CD28-mediated	NULL
signaling	NULL
and	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
T-cell	NULL
gene	NULL
expression	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
stimulation	NULL
of	NULL
normal	NULL
T	NULL
cells	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
mAb	NULL
results	NULL
in	NULL
increased	NULL
nuclear	NULL
rel	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
p50	NULL
.	NULL

Nuclear	NULL
extracts	NULL
contained	NULL
proteins	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
CD28RE	NULL
,	NULL
and	NULL
UV	NULL
crosslinking	NULL
and	NULL
immunoprecipitation	NULL
experiments	NULL
showed	NULL
that	NULL
rel	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
p50	NULL
are	NULL
among	NULL
these	NULL
proteins	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
after	NULL
stimulation	NULL
of	NULL
cells	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
mAb	NULL
.	NULL

The	NULL
functional	NULL
significance	NULL
of	NULL
c-Rel	NULL
involvement	NULL
in	NULL
the	NULL
CD28RC	NULL
was	NULL
demonstrated	NULL
by	NULL
transient	NULL
transfection	NULL
analysis	NULL
,	NULL
where	NULL
cotransfection	NULL
of	NULL
c-rel	NULL
increased	NULL
the	NULL
level	NULL
of	NULL
CAT	NULL
expression	NULL
through	NULL
a	NULL
CD28RE	NULL
.	NULL

These	NULL
findings	NULL
confirm	NULL
an	NULL
earlier	NULL
report	NULL
that	NULL
signaling	NULL
via	NULL
the	NULL
CD28	NULL
molecule	NULL
is	NULL
mediated	NULL
through	NULL
an	NULL
NF	NULL
«	NULL
B-like	NULL
element	NULL
(	NULL
26	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
1699	NULL
The	NULL
sequence	NULL
of	NULL
the	NULL
CD28RE	NULL
,	NULL
as	NULL
defined	NULL
by	NULL
mutational	NULL
analysis	NULL
(	NULL
17	NULL
)	NULL
,	NULL
is	NULL
AAGAAATTCC	NULL
,	NULL
which	NULL
differs	NULL
at	NULL
two	NULL
positions	NULL
from	NULL
the	NULL
consensus	NULL
«	NULL
B	NULL
site	NULL
GGGRNNYYCC	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
Kunsch	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
have	NULL
used	NULL
random	NULL
oligonucleotides	NULL
and	NULL
bacterially	NULL
expressed	NULL
rel	NULL
family	NULL
proteins	NULL
in	NULL
binding	NULL
site	NULL
selection	NULL
experiments	NULL
.	NULL

They	NULL
demonstrated	NULL
that	NULL
ho-modimers	NULL
of	NULL
rel	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
p50	NULL
prefer	NULL
slightly	NULL
different	NULL
binding	NULL
sites	NULL
and	NULL
that	NULL
rel	NULL
has	NULL
the	NULL
least	NULL
stringent	NULL
requirements	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
their	NULL
consensus	NULL
rel	NULL
site	NULL
NGGNNA/TTTCC	NULL
differs	NULL
at	NULL
only	NULL
one	NULL
position	NULL
from	NULL
the	NULL
CD28RE	NULL
,	NULL
while	NULL
the	NULL
consensus	NULL
p50	NULL
site	NULL
GGGGATYCCC	NULL
differs	NULL
at	NULL
five	NULL
positions	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
not	NULL
surprising	NULL
that	NULL
our	NULL
bacterial	NULL
rel	NULL
bound	NULL
CD28RE	NULL
while	NULL
purified	NULL
pS0	NULL
did	NULL
not	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
this	NULL
lack	NULL
of	NULL
p50	NULL
binding	NULL
to	NULL
the	NULL
CD28RE	NULL
,	NULL
we	NULL
detected	NULL
p50	NULL
in	NULL
the	NULL
CD28RC	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
p50	NULL
could	NULL
be	NULL
due	NULL
to	NULL
a	NULL
CD28-signaling-specific	NULL
modification	NULL
of	NULL
p50	NULL
that	NULL
allows	NULL
DNA	NULL
binding	NULL
.	NULL

Alternatively	NULL
,	NULL
p50	NULL
may	NULL
het-erodimerize	NULL
with	NULL
rel	NULL
or	NULL
p65	NULL
and	NULL
thereby	NULL
come	NULL
close	NULL
enough	NULL
to	NULL
the	NULL
DNA	NULL
to	NULL
be	NULL
crosslinked	NULL
after	NULL
UV	NULL
irradiation	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
our	NULL
experiments	NULL
do	NULL
not	NULL
define	NULL
which	NULL
specific	NULL
homo-	NULL
or	NULL
heterodimers	NULL
bind	NULL
the	NULL
CD28RE	NULL
.	NULL

While	NULL
maximum	NULL
nuclear	NULL
translocation	NULL
and	NULL
complex	NULL
induction	NULL
occurred	NULL
when	NULL
PMA	NULL
was	NULL
used	NULL
in	NULL
conjunction	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
treatment	NULL
with	NULL
PMA	NULL
alone	NULL
resulted	NULL
in	NULL
significant	NULL
translocation	NULL
and	NULL
complex	NULL
formation	NULL
.	NULL

This	NULL
is	NULL
somewhat	NULL
surprising	NULL
since	NULL
PMA	NULL
alone	NULL
does	NULL
not	NULL
activate	NULL
T	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
well	NULL
known	NULL
,	NULL
for	NULL
example	NULL
,	NULL
that	NULL
PMA	NULL
does	NULL
not	NULL
induce	NULL
IL-2	NULL
production	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
is	NULL
that	NULL
during	NULL
T-cell	NULL
purification	NULL
some	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
were	NULL
preactivated	NULL
by	NULL
interaction	NULL
with	NULL
B	NULL
cells	NULL
containing	NULL
B7	NULL
,	NULL
the	NULL
ligand	NULL
for	NULL
CD28	NULL
.	NULL

In	NULL
these	NULL
cells	NULL
,	NULL
PMA	NULL
would	NULL
act	NULL
as	NULL
the	NULL
required	NULL
second	NULL
signal	NULL
and	NULL
would	NULL
induce	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
we	NULL
routinely	NULL
monitored	NULL
interferon	NULL
y	NULL
,	NULL
and	NULL
we	NULL
found	NULL
that	NULL
it	NULL
was	NULL
produced	NULL
when	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
or	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
but	NULL
never	NULL
with	NULL
PMA	NULL
alone	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
nuclear	NULL
translocation	NULL
and	NULL
complex	NULL
formation	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
alone	NULL
can	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
preactivation	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

There	NULL
are	NULL
several	NULL
other	NULL
possible	NULL
explanations	NULL
.	NULL

First	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
nuclear	NULL
levels	NULL
of	NULL
critical	NULL
proteins	NULL
do	NULL
not	NULL
reach	NULL
high	NULL
enough	NULL
levels	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
and	NULL
that	NULL
activation	NULL
requires	NULL
the	NULL
higher	NULL
levels	NULL
induced	NULL
by	NULL
the	NULL
second	NULL
signal	NULL
.	NULL

Such	NULL
an	NULL
effect	NULL
has	NULL
been	NULL
documented	NULL
by	NULL
Fiering	NULL
et	NULL
al	NULL
.	NULL

(	NULL
33	NULL
)	NULL
,	NULL
who	NULL
showed	NULL
that	NULL
expression	NULL
controlled	NULL
by	NULL
the	NULL
transcription	NULL
factor	NULL
NF-AT	NULL
requires	NULL
a	NULL
certain	NULL
threshold	NULL
level	NULL
of	NULL
the	NULL
factor	NULL
.	NULL

A	NULL
second	NULL
possibility	NULL
is	NULL
that	NULL
additional	NULL
,	NULL
as	NULL
yet	NULL
unde-fined	NULL
,	NULL
proteins	NULL
are	NULL
induced	NULL
following	NULL
anti-CD28	NULL
mAb	NULL
treatment	NULL
and	NULL
that	NULL
these	NULL
proteins	NULL
are	NULL
required	NULL
for	NULL
active	NULL
complex	NULL
formation	NULL
.	NULL

Third	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
treatment	NULL
might	NULL
result	NULL
in	NULL
some	NULL
type	NULL
of	NULL
posttranslational	NULL
modification	NULL
of	NULL
one	NULL
or	NULL
all	NULL
of	NULL
the	NULL
CD28RE-binding	NULL
proteins	NULL
,	NULL
resulting	NULL
in	NULL
functional	NULL
complex	NULL
formation	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
demonstrating	NULL
CD28-mediated	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
supports	NULL
this	NULL
hypothesis	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
Fraser	NULL
and	NULL
Weiss	NULL
(	NULL
34	NULL
)	NULL
reported	NULL
that	NULL
the	NULL
CD28RC	NULL
contains	NULL
three	NULL
polypeptides	NULL
of	NULL
approximately	NULL
35	NULL
,	NULL
36	NULL
,	NULL
and	NULL
44	NULL
kDa	NULL
.	NULL

There	NULL
are	NULL
several	NULL
differences	NULL
between	NULL
our	NULL
protocol	NULL
and	NULL
theirs	NULL
that	NULL
could	NULL
contribute	NULL
to	NULL
the	NULL
different	NULL
results	NULL
.	NULL

First	NULL
,	NULL
they	NULL
used	NULL
a	NULL
T-cell	NULL
line	NULL
for	NULL
their	NULL
studies	NULL
,	NULL
while	NULL
we	NULL
used	NULL
purified	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

Second	NULL
,	NULL
they	NULL
stimulated	NULL
cells	NULL
for	NULL
2	NULL
hr	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
7	NULL
hr	NULL
in	NULL
our	NULL
case	NULL
.	NULL

Third	NULL
,	NULL
their	NULL
oligonucleotide	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
granulocyte-macrophage/colony-stimulating	NULL
factor	NULL
promoter	NULL
,	NULL
not	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
and	NULL
there	NULL
are	NULL
minor	NULL
differences	NULL
between	NULL
them	NULL
.	NULL

Lastly	NULL
,	NULL
we	NULL
,	NULL
but	NULL
not	NULL
they	NULL
,	NULL
used	NULL
a	NULL
bromouridine-substituted	NULL
oligonucleotide	NULL
in	NULL
the	NULL
crosslinking	NULL
studies	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Carl	NULL
H.	NULL
June	NULL
for	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
Dr.	NULL
Robert	NULL
Roeder	NULL
for	NULL
affinity-purified	NULL
p50	NULL
protein	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Earl	NULL
W.	NULL
Bere	NULL
for	NULL
purified	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
and	NULL
Drs	NULL
.	NULL

John	NULL
Ortaldo	NULL
and	NULL
Dan	NULL
Longo	NULL
for	NULL
their	NULL
critical	NULL
review	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

This	NULL
research	NULL
was	NULL
sponsored	NULL
by	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Department	NULL
of	NULL
Health	NULL
1700	NULL
Immunology	NULL
:	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

and	NULL
Human	NULL
Services	NULL
,	NULL
under	NULL
Contract	NULL
NO1-CO-74101	NULL
with	NULL
ABL	NULL
and	NULL
Contract	NULL
NO1-CO-74102	NULL
with	NULL
Program	NULL
Resources	NULL
,	NULL
Inc./DynCorp	NULL
.	NULL

1	NULL
.	NULL

2	NULL
.	NULL

3	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
1349-1356	NULL
.	NULL

Springer	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
346	NULL
,	NULL
425-434	NULL
.	NULL

Muller	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
&	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
445-480	NULL
.	NULL

Kohno	NULL
,	NULL
K.	NULL
,	NULL
Shibata	NULL
,	NULL
Y.	NULL
,	NULL
Matsuo	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Minowada	NULL
,	NULL
J	NULL
.	NULL

€990	NULL
)	NULL
Cell	NULL
.	NULL

Immunol	NULL
.	NULL

131	NULL
,	NULL
1-10	NULL
.	NULL

Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
&	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165	NULL
,	NULL
302-319	NULL
.	NULL

Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Pardoll	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Mizuguchi	NULL
,	NULL
J.	NULL
,	NULL
Chused	NULL
,	NULL
T.	NULL
M.	NULL
&	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84	NULL
,	NULL
5409-5413	NULL
.	NULL

Quill	NULL
,	NULL
H.	NULL
&	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

138	NULL
,	NULL
3704-3712	NULL
.	NULL

Hara	NULL
,	NULL
T.	NULL
,	NULL
Fu	NULL
,	NULL
S.	NULL
M.	NULL
&	NULL
Hansen	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

161	NULL
,	NULL
1513-1524	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
&	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
11	NULL
,	NULL
211-216	NULL
.	NULL

Harding	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
McArthur	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Gross	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Raulet	NULL
,	NULL
D.	NULL
H.	NULL
&	NULL
Allison	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
356	NULL
,	NULL
607-609	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Gillespie	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
&	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
4472-4481	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Emerson	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
1333-1337	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Clark	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

&	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
,	NULL
5031-5035	NULL
.	NULL

Koulova	NULL
,	NULL
L.	NULL
,	NULL
Clark	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Shu	NULL
,	NULL
G.	NULL
&	NULL
Dupont	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173	NULL
,	NULL
759-762	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Brady	NULL
,	NULL
W.	NULL
,	NULL
Grosmaire	NULL
,	NULL
L..	NULL
,	NULL
Aruffo	NULL
,	NULL
A.	NULL
,	NULL
Damle	NULL
,	NULL
N.	NULL
K.	NULL
&	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173	NULL
,	NULL
721-730	NULL
.	NULL

Gimmi	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Sugita	NULL
,	NULL
K.	NULL
,	NULL
Freedman	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Morimoto	NULL
,	NULL
C.	NULL
&	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
6575-6579	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
313-316	NULL
.	NULL

Vandenberghe	NULL
,	NULL
P.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Fletcher	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Turka	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Thom-pason	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

&	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
951-960	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
MacKichan	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
243-253	NULL
.	NULL

Tan	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Huang	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
&	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4067-4075	NULL
.	NULL

Kadonaga	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Carner	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Masiarz	NULL
,	NULL
F.	NULL
R.	NULL
&	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
51	NULL
,	NULL
1079-1090	NULL
.	NULL

Sica	NULL
,	NULL
S.	NULL
,	NULL
Tan	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
,	NULL
Kretzschmar	NULL
,	NULL
M.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
&	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
1740-1744	NULL
.	NULL

Tan	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Horikoshi	NULL
,	NULL
M.	NULL
&	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9	NULL
,	NULL
1733-1745	NULL
.	NULL

Kochel	NULL
,	NULL
T.	NULL
&	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Oncogene	NULL
7	NULL
,	NULL
567-572.	NULL
de	NULL
Belle	NULL
,	NULL
I.	NULL
,	NULL
Walker	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Smith	NULL
,	NULL
I.	NULL
C.	NULL
P.	NULL
&	NULL
Sikorska	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
2752-2759	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Luciw	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Peterlin	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
702-707	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Gillespie	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
&	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
4472-4481	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
&	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

143	NULL
,	NULL
153-161	NULL
.	NULL

Ruben	NULL
,	NULL
S.	NULL
,	NULL
Poteat	NULL
,	NULL
H.	NULL
,	NULL
Tan	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Kawakami	NULL
,	NULL
K.	NULL
,	NULL
Roeder	NULL
,	NULL
R.	NULL
,	NULL
Haseltine	NULL
,	NULL
W.	NULL
&	NULL
Rosen	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
89-92	NULL
.	NULL

Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Geerts	NULL
,	NULL
M.	NULL
&	NULL
Aarden	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
14179-14182	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
63-80	NULL
.	NULL

Kunsch	NULL
,	NULL
C.	NULL
,	NULL
Ruben	NULL
,	NULL
S.	NULL
M.	NULL
&	NULL
Rosen	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4412-4421	NULL
.	NULL

Fiering	NULL
,	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

4	NULL
,	NULL
1823-1834	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
&	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4357-4363	NULL
.	NULL

